Together, the pharmacological inhibition of HAS enzymatic activity or HAS3 neutralization mimicked HAS3 depletion effects on oral cancer cells, supporting that HA accumulation was accountable for oncogenic actions mediated by HAS3. The gene discussed is HAS1; the disease is lip and oral cavity carcinoma.